Cytox Company
Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.
Investors
Funding Status:
Early Stage Venture
Industry:
Clinical Development
Estimated Revenue:
$10M to $50M
Technology:
Biotechnology, Genetics
Headquarters:
Manchester, Manchester, United Kingdom
Total Funding:
15484781.0
Last Funding Date:
2019-01-01
Last Funding Type:
Grant
Employee Number:
1-10
Investors Number:
16.0
Founded Date:
2004-01-01